NCT06657144

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 154 (estimated)
• Sponsor: Coherus Oncology, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Conditions

• Metastatic Solid Tumor
• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	CHS-114	Solution for infusion
DRUG	Toripalimab	Solution for infusion
DRUG	5 Fluorouracil	Solution for infusion
DRUG	Cisplatin	Solution for infusion

Timeline

• Start date: 2025-04-01
• Primary completion: 2028-01-01
• Completion: 2028-01-01
• First posted: 2024-10-24
• Last updated: 2026-04-06

Locations

30 sites across 2 countries: United States, Taiwan

Regulatory

• FDA-regulated drug study